Tofacitinib: The Selected Selective JAK Inhibitor in Pediatric Dermatology
January 2024
in “
International Journal of Dermatology Venereology and Leprosy Sciences
”
Studysummary This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on dermatologypaper.com →